• Are newer female sex workers (FSWs) more vulnerable to HIV ? Comparison of key behavioural indicators from integrated biological and behavioural surveillance (IBBS) survey among FSWs in Kathmandu more
  • ARE PATIENTS UNDERGOING PGD FOR CHROMOSOME REARRANGEMENTS AT INCREASED RISK OF ANEUPLOIDY AFFECTING CHROMOSOMES UNRELATED TO THEIR REARRANGEMENT (INTERCHROMOSOMAL EFFECT)? more
  • Are patients with Parkinson's disease who have either mild to moderate microsmia, severe microsmia or anosmia clinically different? more
  • Are Photogrammetry and 3D Scanning a real alternative to 3D modelling for Virtual Heritage applications? more
  • Are student midwives equipped to support normal birth? more
  • ARE SWEETNESS PREFERENCES MODIFIABLE? THE DEVELOPMENT OF THE PRIMARY OUTCOME VARIABLE TO ASSESS THE EFFECTS OF SWEETNESS EXPOSURE ON PREFERENCES more
  • Are there differences in cervical inter-vertebral laxity or translation motion between patients with neck pain and healthy controls? more
  • Are UK Nature Conservation Laws Fit for Purpose? more
  • Are UK universities marketing themselves effectively to UK blue chip employers? more
  • Are UK universities more ethical than police organisations? more
  • Are We Raising Media Critics or Cynics? more
  • Are we there yet? more
  • Are we there yet? more
  • Are We Underestimating the Psychosocial Rehabilitation Needs of the Occupationally Injured Burn Patient? more
  • Are Web Development Methods Too Difficult To Use? more
  • Are You There: Material and Immaterial more
  • Are You There: the relationship between film and screen more
  • ARElight: Context Sampling of Large Texts for Deep Learning Relation Extraction more
  • Arsenic in the bengal delta plain: Geochemical complications and potential mitigation option more
  • Art in Corporate Governance: a Deweyan Perspective on Board Experience more
  • Art in Flux at EVENT 2 more
  • ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer: primary endpoint – pathological complete response (pCR) more
  • ARTemis: A randomised trial of bevacizumab with neoadjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer-Primary endpoint, pathological complete response (pCR). more
  • ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy for patients with HER2-negative early breast cancer more
  • Article 102 TFEU and software interoperability post-Microsoft: the limits of the "exceptional circumstances test" more

Previous Next